- Home
- LILA vs COGT Comparison
LILA vs COGT Comparison
Compare LILA & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LILA
- COGT
- Stock Information
- Founded
- LILA 2017
- COGT 2014
- Country
- LILA Bermuda
- COGT United States
- Employees
- LILA N/A
- COGT N/A
- Industry
- LILA Cable & Other Pay Television Services
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- LILA Telecommunications
- COGT Health Care
- Exchange
- LILA Nasdaq
- COGT Nasdaq
- Market Cap
- LILA 1.3B
- COGT 1.1B
- IPO Year
- LILA N/A
- COGT 2018
- Fundamental
- Price
- LILA $7.75
- COGT $12.56
- Analyst Decision
- LILA Sell
- COGT Strong Buy
- Analyst Count
- LILA 1
- COGT 11
- Target Price
- LILA $6.50
- COGT $21.20
- AVG Volume (30 Days)
- LILA 452.8K
- COGT 1.5M
- Earning Date
- LILA 11-05-2025
- COGT 11-11-2025
- Dividend Yield
- LILA N/A
- COGT N/A
- EPS Growth
- LILA N/A
- COGT N/A
- EPS
- LILA N/A
- COGT N/A
- Revenue
- LILA $4,409,700,000.00
- COGT N/A
- Revenue This Year
- LILA $1.21
- COGT N/A
- Revenue Next Year
- LILA $2.90
- COGT N/A
- P/E Ratio
- LILA N/A
- COGT N/A
- Revenue Growth
- LILA N/A
- COGT N/A
- 52 Week Low
- LILA $4.26
- COGT $3.72
- 52 Week High
- LILA $10.79
- COGT $13.50
- Technical
- Relative Strength Index (RSI)
- LILA 54.34
- COGT 56.24
- Support Level
- LILA $7.46
- COGT $12.28
- Resistance Level
- LILA $8.14
- COGT $13.13
- Average True Range (ATR)
- LILA 0.23
- COGT 0.50
- MACD
- LILA -0.08
- COGT -0.06
- Stochastic Oscillator
- LILA 45.39
- COGT 42.94
About LILA Liberty Latin America Ltd.
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.